Novartis ends Fabhalta trial for lupus kidney disease

Novartis has stopped a Phase 2 trial of its drug iptacopan for lupus nephritis. The company's shares declined, contributing to a downbeat start for Switzerland's blue-chip index. This decision may impact Novartis's pipeline and investor sentiment.

Novartis halted a mid-stage trial for a lupus nephritis drug. The company's shares declined, contributing to a downbeat start for Switzerland's blue-chip index. The decision may impact investor sentiment toward Novartis' pipeline and future prospects.

Novartis AG (NYSE:NVS) reported 1% net sales growth in Q2, with higher volumes offset by generic competition and lower prices. Key drugs like Kisqali and Kesimpta showed strong growth, contributing 30% of revenue. The company's forward P/E is 14.71, and it generated $5.6B in free cash flow. Investors are evaluating its ability to replace revenue from older medicines.

Novartis halted a Phase 2 study of Fabhalta (iptacopan) for lupus nephritis due to strategic reasons, not efficacy or safety concerns. The drug is approved for other conditions and generated $505M in sales last year. Novartis continues studying Fabhalta in other indications and remains committed to lupus nephritis research with another study.

Novartis halted a mid-stage trial of Fabhalta for lupus nephritis after completing the first part, without disclosing reasons. The drug is approved for PNH and two kidney diseases. The company did not comment.

Novartis (NYSE: NVS) halted a mid-stage trial of Fabhalta for lupus nephritis due to strategic reasons, not efficacy or safety concerns. The study, which began in 2022, was evaluating Fabhalta alongside standard treatments. Other Fabhalta trials will continue. Fabhalta is already approved for three conditions, including paroxysmal nocturnal haemoglobinuria and two kidney diseases.